{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:41:57Z","timestamp":1789674117173,"version":"4.0.1"},"reference-count":43,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Carbapenem\u2010resistant\n                    <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                    (CRAB) is a difficult\u2010to\u2010treat nosocomial pathogen responsible for significant morbidity and mortality. Sulbactam\u2010durlobactam (SUL\u2010DUR), formerly ETX2514SUL, is a novel \u03b2\u2010lactam\u2010\u03b2\u2010lactamase inhibitor designed specifically for the treatment of CRAB infections. The United States Food and Drug Administration (FDA) fast\u2010track approval of SUL\u2010DUR for the treatment of CRAB infections is currently pending after completion of the phase III ATTACK trial, which compared SUL\u2010DUR to colistin, both in combination with imipenem\u2010cilastatin (IMI) for patients with CRAB\u2010associated hospital\u2010acquired bacterial pneumonia, ventilator\u2010associated pneumonia, and bacteremia. The results of this trial demonstrated that SUL\u2010DUR was non\u2010inferior to colistin for CRAB while also possessing a much more favorable safety profile. SUL\u2010DUR was well\u2010tolerated with the most common side effects being headache, nausea, and injection\u2010site phlebitis. With the current landscape of limited effective treatment options for CRAB infections, SUL\u2010DUR represents a promising therapeutic option for the treatment of these severe infections. This review will discuss the pharmacology, spectrum of activity, pharmacokinetics\/pharmacodynamics, in vitro and clinical studies, safety, dosing, administration, as well as the potential role in therapy for SUL\u2010DUR.\n                  <\/jats:p>","DOI":"10.1002\/phar.2802","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T06:02:14Z","timestamp":1681365734000},"page":"502-513","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Sulbactam\u2010durlobactam: A novel \u03b2\u2010lactam\u2010\u03b2\u2010lactamase inhibitor combination targeting carbapenem\u2010resistant\n                    <i>Acinetobacter baumannii<\/i>\n                    infections"],"prefix":"10.1002","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1744-0048","authenticated-orcid":false,"given":"Amer","family":"El\u2010Ghali","sequence":"first","affiliation":[{"name":"Anti\u2010Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University  Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4891-8625","authenticated-orcid":false,"given":"Ashlan J.","family":"Kunz\u00a0Coyne","sequence":"additional","affiliation":[{"name":"Anti\u2010Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University  Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1468-8267","authenticated-orcid":false,"given":"Kaylee","family":"Caniff","sequence":"additional","affiliation":[{"name":"Anti\u2010Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University  Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callan","family":"Bleick","sequence":"additional","affiliation":[{"name":"Anti\u2010Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University  Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2220-0081","authenticated-orcid":false,"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[{"name":"Anti\u2010Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University  Detroit Michigan USA"},{"name":"Department of Pharmacy Services, Detroit Receiving Hospital Detroit Medical Center  Detroit Michigan USA"},{"name":"Division of Infectious Diseases, Department of Medicine Wayne State University  Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:82532"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00058-16"},{"key":"e_1_2_15_5_1","volume-title":"COVID\u201019: U.S. Impact on Antimicrobial Resistance, Special Report 2022","year":"2022"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.709974"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2017.104"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.07.012"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01089-18"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00794-19"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01506-19"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.02.012"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00159-19"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.08.026"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.001"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10070769"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz440"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.485979"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01659-18"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.12.101"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad096"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00781-22"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa208"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.814530"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa119"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.05.001"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9040205"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jam.15130"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9030119"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01576-17"},{"key":"e_1_2_15_32_1","doi-asserted-by":"crossref","unstructured":"AltaracD ShapiroB RanaK LewisD.Sulbactam\u2010durlobactam treatment is associated with lower mortality from index acinetobacter infections in the ATTACK Phase 3 registrational trial. Poster presented at: American Thoracic Society; 2022 May 16; San Francisco CA.","DOI":"10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A5620"},{"key":"e_1_2_15_33_1","doi-asserted-by":"crossref","unstructured":"LewisD RanaK SteidlerM.Safety profile of sulbactam\u2010durlobactam (SUL\u2010DUR) versus colistin therapy in patients withAcinetobacter baumannii\u2010calcoaceticuscomplex (ABC) infections from the phase III global randomised active\u2010controlled trial (ATTACK). Poster presented at: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2022 April 23; Lisbon Portugal.","DOI":"10.1093\/ofid\/ofac492.727"},{"key":"e_1_2_15_34_1","unstructured":"AltaracD IsaacR SrinivasanS.Efficacy and safety of sulbactam\u2010durlobactam (SUL\u2010DUR) therapy in patients withAcinetobacter baumannii\u2010calcoaceticuscomplex (ABC) infections in the open label part B of the ATTACK phase III trial. Poster presented at: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2022 April 23; Lisbon Portugal."},{"key":"e_1_2_15_35_1","unstructured":"MillerAA McLeodSM ChabasD.Characterisation ofAcinetobacter baumannii\u2010calcoaceticuscomplex (ABC) pathogens isolated at baseline from patients enrolled in the ATTACH phase III trial. 2022 April 23; Lisbon Portugal."},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01424-21"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac092"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00071-20"},{"key":"e_1_2_15_39_1","doi-asserted-by":"crossref","unstructured":"LickliterJ O'DonnellJ IsaacsR.Safety and pharmacokinetics (PK) in humans of intravenous ETX2514 a B\u2010lactamase inhibitor (BLI) which broadly inhibits ambler class A C and D B\u2010lactamases. Poster presented at: ID Week; 2017 October; San Diego.","DOI":"10.1093\/ofid\/ofx163.1366"},{"key":"e_1_2_15_40_1","unstructured":"CarterNM MillerA.In vitro activity of sulbactam\u2010durlobactam in combination with other antimicrobial agents. Presentation presented at: ID Week 2022; 2022 October; Washington DC."},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12991"},{"key":"e_1_2_15_42_1","unstructured":"AltaracD IsaacsR SrinivasanS et al.Efficacy and safety of sulbactam\u2010durlobactam (SUL\u2010DUR) versus colistin therapy in patients withAcinetobacter baumannii\u2010calcoaceticuscomplex (ABC) infections: a global randomized active\u2010controlled phase 3 trial (ATTACK). Presentation presented at: ECCMID 2022; 2022 April; Lisbon Portugal."},{"key":"e_1_2_15_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0902-x"},{"key":"e_1_2_15_44_1","unstructured":"SMML.Sulbactam\u2010durlobactam (SUL\u2010DUR) a targeted \u03b2\u2010lactam\/\u03b2\u2010lactamase inhibitor for MDR Acinetobacter infections. Presentation presented at: ASM Microbe; 2022 June 10; Washington DC."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:23:13Z","timestamp":1761056593000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1002\/phar.2802"],"URL":"https:\/\/doi.org\/10.1002\/phar.2802","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"2023-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}